The use of antibodies is pervasive in the biological sciences. Finding the best research procedures, nevertheless, has not been simple. Numerous widely deployed antibodies and antibody conjugates lack proper validation and are ineffective. The dilemma of reproducibility in biomedical research has been exacerbated by the uncritical deployment of such ineffective technologies.
While antibodies can theoretically be used in nearly every field, the practice is more complex than one may anticipate. Antibody-related products often lack proper validation and access to crucial empirical observations. This article will go over the steps involved in creating antibodies, the mistakes that can happen, and potential fixes that could assist in creating high-quality antibodies.
Production of Antibodies
What is antibody production? The phrase "antibody production" has both broad and detailed connotations. In a broad sense, it refers to all steps involved in producing specific antibodies, such as immunogen synthesis, immunization, the creation of hybridomas, screening, and purification. In a stricter sense, the definition refers specifically to the actual manufacturing steps. There are several approaches for producing antibodies as a result of technological advancements. Hybridoma cells can be used in vitro to make monoclonal antibodies, while the majority of polyclonal antibodies are produced in rabbits.
The generation of antibodies is a characteristic of the immune system's adaptive response. The purpose of antibodies is to neutralize or eliminate pathogens or antigens. B lymphocytes (B cells) generate antibodies after differentiating into plasma cells. Animals immunized against a chosen antigen can aid in polyclonal antibody (pAb) production. There are several quantitative, forensic, and pharmacological uses for pAbs. pAbs have been employed to stop illnesses like diphtheria since 1894.
Preparing antigen samples and safely injecting them into farm or laboratory animals results in significant levels of antigen-specific antibodies being expressed in the serum, which may subsequently be collected. Polyclonal antibody production begins with serum (a blood sample). Monoclonal antibodies are created by combining immortalized myeloma cells with antibody-secreting splenocytes from immunized mice to create a monoclonal hybridoma cell line that expresses specific antibodies inside the cell culture supernatant.
Peptides also play a significant role in antibody production. Therefore, before you start the antibody production process, you often start with peptide synthesis.
Antibody Purification
Antibody purification involves the isolation of specific antibodies from serum (for polyclonal antibodies) or from cell culture supernatant or ascites fluid (for monoclonal antibodies). Antibody purification methods range from crude to highly specific and are generally classified as follows:
- Physicochemical fractionation: This includes size exclusion, differential precipitation, or solid-phase binding of immunoglobulins based on charge, size, or other shared chemical features. These methods help isolate a subset of sample proteins, including immunoglobulins.
- Class-specific affinity: This method purifies all antibodies of a particular class without considering antigen specificity. Examples include solid-phase binding of antibody classes like IgG using immobilized biological ligands, such as Protein A, Protein G, or lectins.
- Antigen-specific affinity: This involves the purification of antibodies that bind to a specific antigen molecule using their antigen-binding domains. It isolates all antibodies that bind the antigen, regardless of antibody isotype or class.
Antibodies produced as supernatant or ascites fluid from monoclonal antibody hybridoma cell lines can often be purified without using antigen-specific affinity methods. This is because the target antibody is usually the only immunoglobulin in the sample. In contrast, for polyclonal antibodies (from serum samples), antigen-specific affinity purification is often necessary. This prevents the co-purification of non-specific immunoglobulins. For example, mouse serum may contain as little as 2-5% specific IgG relative to the total IgG. This degree of purification is essential to extract usable antibodies.
Standard methods used in antibody purification include:
-
Size exclusion chromatography
-
Ammonium sulfate precipitation
-
Ion exchange chromatography
-
Immobilized metal chelate chromatography
-
Thiophilic adsorption
-
Melon Gel chromatography
During antibody purification, mistakes can happen that affect the quality of the final product. Purification is essential to ensure pure antibodies free from contamination.
The use of the wrong purification methods or reagents is a common mistake. To avoid this, it is best to research the optimal purification method for a given antibody or consult experts. By understanding the three classifications of purification methods, ranging from crude to highly specific, you can identify which method is suitable for your antibody. Another possible mistake during purification is impatience; specifically, failing to give your sample enough time to equilibrate or flow through the chromatography process.
Errors Made in Antibody Production
1. Contamination of Production Materials
Temperature fluctuations and contamination are two fundamentally preventable issues in antibody synthesis. Improper specimen handling during transit or within the laboratory can cause temperature changes and stress to cell lines. Strained cells can significantly impair antibody production, necessitating extensive effort to restore the cell line to optimal productivity. The effectiveness of the process is maintained by careful sample preservation throughout the transit phase, which guarantees an ideal temperature is maintained.
Scientists warn that antibodies may cross-react with proteins other than their primary targets if they lack the precision required for their intended application. Over the past 30 years, mycoplasma contamination and other adventitious agents have become a lesser danger, but they are still a concern. Contamination is not always visible when it occurs. However, once the cell culture starts to decline, it can significantly influence productivity by changing how cells behave and function.
The risk of contamination can be reduced by using well-documented laboratory techniques, tested media and supplements from reliable vendors, and appropriate cell and apparatus segregation. Extensive validation can establish antibody specificity, enhancing the quality and repeatability of study findings. Rigorous validation of the antibodies employed in assay development ensures high specificity and speeds up the process of providing patients who require them with appropriate medicines.
2. Inability to Wait Patiently Throughout the Manufacturing
Specific cell lines are often initially established to address a research question for a short-term endeavor. As a project gains commercial potential, the cell line is then assessed for its economic viability. However, productivity could be at risk if cells are developed too quickly or incorrectly in an attempt to accelerate synthesis. In this scenario, the customer may be left with a cell line that increases manufacturing costs, or the cell line may require significantly more resources and time to function optimally.
In these circumstances, laboratory patience is genuinely a virtue. It is advised that researchers allot enough time to develop their lines and strategically design a comprehensive project plan for the cells. Anticipating a cell line's potential for commercialization will assist in guiding its advancement and help in selecting the best development partners who can swiftly scale up to production levels.
3. The Utilization of Faulty Identifier, Validation, and Standardization Tools
An antibody may only bind the target used during immunization. All too frequently, the immunization strategy is chosen without considering the final application. As a result, industrial antibody manufacturers must address the rising need for better methods of standardization and validation. The antibody production community should revive ground-breaking standardization goals and update "Minimum information about a protein affinity reagent" (MIAPAR) and "Proteomics Standards Initiative-Protein affinity binders" (PSI-PAR) to create a more straightforward, standardized framework for affinity binders.
By employing sound research procedures, the drawbacks of monoclonal antibodies and polyclonal sera can be minimized so that the benefits far exceed them. It is hard to ignore the importance of antibody sequencing services for reliable recombinant protein production. However, the relative scarcity of sequence information often leads to a lack of consistent evaluations of antigen binding. With suitable research methods, sequencing antibodies becomes an asset rather than simply a requirement in most use cases.
Additionally, it is crucial to correctly identify antibodies to prevent research findings from being unreproducible and to avoid product confusion caused by the rebranding of individual antibodies. Antigen-binding subunit sequencing is only one method for giving different binders a distinctive, long-lasting identity. Identifying preexisting antibodies in published papers will also be aided by other initiatives, such as the Research Resource Identifier (RRID). The medical and scientific community should strive to avoid fragmentation of antibody identification systems and settle on a single identifier platform with standard protocols.
4. Unreliable Information Streams
Once a production partner has been chosen, as much information as possible must be communicated. Clearly inform the partner of the product's ultimate goal. For instance, is this project only a feasibility test? Does this pertain to a product that will ultimately be commercialized to satisfy market needs? Will this item be licensed and become subject to particular regulatory compliance? These specifics assist the development partner in planning for expansion and preparing to gather the necessary data for subsequent milestones.
The development partner must also communicate promptly and effectively to keep their clients updated on challenges and accomplishments. For instance, if a customer expects purified material in four to seven weeks and the development partner encounters problems with the product, they must immediately report these issues and address the customer’s requirements.
Monoclonal Antibody Production Cost
The identification, optimization, production, and delivery of more effective, less expensive monoclonal antibody treatments should all be aided by technological advancements, according to a new paper from the Wellcome Trust and IAVI.
The monoclonal antibody production cost is substantial, making it one of the main obstacles to access in Low- and Middle-Income Countries (LMICs), as is their premium price. The quantity of mAbs per dose, the treatment regimen (the number of doses required), market requirements, and manufacturing scale all affect the cost of goods to create mAbs. The cost of manufacturing today is pegged at $US95 and $200 per gram.
LMICs are unlikely to be able to afford monoclonal antibody products if large amounts are needed. This makes the business case for mAbs targeting antimicrobial resistance challenging, especially in light of existing or ongoing research into alternative therapies such as vaccines or chemically synthesized small-molecule medicines. Consequently, efforts are being made to find other methods to cut costs, such as using different cell lines, new production techniques, and updated infrastructure.
To further encourage the creation of innovative business and procurement strategies, such as advanced market commitments, collective sourcing, and tiered pricing, clarifying mAb applications, demand forecasting, and comprehensive value evaluations will be helpful.
Antibody Quality Testing
Regularly check each employed antibody's specificity, selectivity, and reproducibility. The next step for researchers is to evaluate the antibodies' sensitivity and specificity to ensure that results can be repeated. It is crucial to run these tests within the framework of a particular application. Antibodies, for instance, may be employed to target proteins in complicated biological matrices or purified materials and to discern native or denatured proteins. Specific criteria are needed for every application to evaluate such antibodies' effectiveness.
To serve as antigen-specific detectors, antibodies are produced and purified. Nevertheless, a method for subsequent antibody validation is necessary for their use in any specific procedure, such as ELISA kits or cell imaging.
In Conclusion
Custom antibody manufacturing will continue to be challenging; however, one can improve the likelihood of success by implementing a proactive plan to prevent typical mistakes. By studying real-world success stories, you can learn more about how your final products should perform. One must start with an unbiased perspective and consider whether polyclonal or monoclonal antibodies are the best fit for a particular application, depending on the antibody's intended use.
Thorough research, consultation, and continuous practice can help refine your skills and experience, which will help you avoid mistakes in the antibody production process. In addition, by leveraging technological advancements, you can utilize both established and modified methods in production and purification, which will help you significantly reduce errors.